Fujian Haixi Pharmaceuticals (HKG:2637) officially began a phase III clinical trial of the C019199 tablets, according to a Friday Hong Kong bourse filing.
The trial aims to evaluate the efficacy and safety of the drug for the treatment of osteosarcoma after the failure of at least two prior lines of therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments